12 Month Price Forecast For MGX
Distance to MGX Price Forecasts
MGX Price Momentum
๐ค Considering Metagenomi (MGX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 6:03 PM UTC
MGX Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, MGX has a bullish consensus with a median price target of $17.00 (ranging from $14.00 to $25.00). Currently trading at $2.61, the median forecast implies a 551.3% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yanan Zhu at Wells Fargo, projecting a 857.9% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 436.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGX Analyst Consensus
MGX Price Target Range
Latest MGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 10, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $14.00 |
Nov 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
Nov 20, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
Oct 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
Sep 6, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
Sep 5, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
Aug 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $7.00 |
Aug 19, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
Aug 15, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $17.00 |
Jul 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $10.00 |
May 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $10.00 |
May 7, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $10.00 |
May 2, 2024 | JP Morgan | Brian Cheng | Neutral | Downgrade | $6.00 |
Mar 28, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $21.00 |
Mar 5, 2024 | TD Cowen | Joseph Thome | Outperform | Initiates | $0.00 |
Mar 5, 2024 | Jefferies | Maury Raycroft | Buy | Initiates | $23.00 |
Mar 5, 2024 | BMO Capital | Kostas Biliouris | Outperform | Initiates | $22.00 |
Mar 5, 2024 | Wells Fargo | Yanan Zhu | Overweight | Initiates | $25.00 |
Mar 5, 2024 | Chardan Capital | Geulah Livshits | Buy | Initiates | $21.00 |
Mar 5, 2024 | JP Morgan | Brian Cheng | Overweight | Initiates | $16.00 |
Stocks Similar to Metagenomi, Inc. Common Stock
The following stocks are similar to Metagenomi based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Metagenomi, Inc. Common Stock (MGX) Financial Data
Metagenomi, Inc. Common Stock has a market capitalization of $97.68M with a P/E ratio of -1.4x. The company generates $55.08M in trailing twelve-month revenue with a -134.3% profit margin.
Revenue growth is -6.9% quarter-over-quarter, while maintaining an operating margin of -194.4% and return on equity of -30.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Metagenomi, Inc. Common Stock (MGX) Company Overview
About Metagenomi, Inc. Common Stock
Develops genetic therapeutics using genome editing.
Metagenomi, Inc. operates by creating advanced genetic medicines utilizing its proprietary genome editing toolbox, which includes various innovative technologies. The company monetizes its research through development, option, and license agreements with partners such as Affini-T Therapeutics and Ionis Pharmaceuticals, allowing it to share costs and revenues from the commercialization of gene therapies.
Founded in 2016 and based in Emeryville, California, Metagenomi focuses on treating, preventing, or diagnosing human cancer, positioning itself in the rapidly growing genetic medicine sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
236
CEO
Dr. Brian Charles Thomas Ph.D.
Country
United States
IPO Year
2024
Website
www.metagenomi.coMetagenomi, Inc. Common Stock (MGX) Latest News & Analysis
Metagenomi, Inc. (Nasdaq: MGX) CEO Brian C. Thomas will speak at TD Cowen's Health Care Conference on March 5, 2025, and the company will hold one-on-one investor meetings.
Metagenomi's participation in a prominent healthcare conference highlights its strategic efforts to engage with investors and showcase its gene editing innovations, potentially influencing stock performance.
Metagenomi, Inc. has appointed Eric Bjerkholt, CFO of Mirum Pharmaceuticals, to its Board of Directors, effective January 27, 2025. He will serve on the Audit and Compensation committees.
Eric Bjerkholt's appointment to Metagenomi's Board could enhance financial oversight and strategic direction, potentially leading to improved investor confidence and stock performance.
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
30 days agoMetagenomi, Inc. (MGX) is advancing MGX-001 for Hemophilia A towards regulatory interactions in 2025, with cash runway expected to support operations into 2027.
Metagenomi's advancements in gene editing for Hemophilia A and cardiometabolic indications signal potential growth and innovation, enhancing investor confidence in future performance and product viability.
Metagenomi, Inc. (Nasdaq: MGX) will present at the J.P. Morgan Healthcare Conference on January 15, 2025, at 4:30 p.m. PT, showcasing its gene editing technologies.
Metagenomi's presentation at a major healthcare conference can attract investor interest, highlight advancements in gene editing, and potentially influence stock performance based on market reactions.
Metagenomi, Inc. (Nasdaq: MGX) showcased its MGX-001 gene editing tool, highlighting its precision and safety in human cells, at the Nature Conference on December 11, 2024.
Metagenomi's advancements in precise gene editing with no off-target effects could enhance its product pipeline, potentially leading to significant therapeutic breakthroughs and increased investor confidence.
A nonhuman primate study shows sustained therapeutic levels of Factor VIII activity for over 16 months, indicating potential for long-term efficacy in treatments.
Sustained Factor VIII activity in NHP studies signals potential for effective hemophilia treatments, which could boost company valuations and attract investment in biopharma sectors.
Frequently Asked Questions About MGX Stock
What is Metagenomi, Inc. Common Stock's (MGX) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Metagenomi, Inc. Common Stock (MGX) has a median price target of $17.00. The highest price target is $25.00 and the lowest is $14.00.
Is MGX stock a good investment in 2025?
According to current analyst ratings, MGX has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MGX stock?
Wall Street analysts predict MGX stock could reach $17.00 in the next 12 months. This represents a 551.3% increase from the current price of $2.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Metagenomi, Inc. Common Stock's business model?
Metagenomi, Inc. operates by creating advanced genetic medicines utilizing its proprietary genome editing toolbox, which includes various innovative technologies. The company monetizes its research through development, option, and license agreements with partners such as Affini-T Therapeutics and Ionis Pharmaceuticals, allowing it to share costs and revenues from the commercialization of gene therapies.
What is the highest forecasted price for MGX Metagenomi, Inc. Common Stock?
The highest price target for MGX is $25.00 from Yanan Zhu at Wells Fargo, which represents a 857.9% increase from the current price of $2.61.
What is the lowest forecasted price for MGX Metagenomi, Inc. Common Stock?
The lowest price target for MGX is $14.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 436.4% increase from the current price of $2.61.
What is the overall MGX consensus from analysts for Metagenomi, Inc. Common Stock?
The overall analyst consensus for MGX is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are MGX stock price projections?
Stock price projections, including those for Metagenomi, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.